Trial Search Results

Telotristat Etiprate for Carcinoid Syndrome Therapy

Carcinoid syndrome occurs when carcinoid tumors produce too many hormones and other substances that normally circulate throughout your body. The most common symptoms of carcinoid syndrome are diarrhea and redness (flushing) of the face, chest, or back. Other symptoms include changes in the structure of the heart valves that can impair theheart's function (heart valvular lesions) and abdominal pain and cramping. The purpose of this study is to evaluate an investigational drug called LX1606, developed by Lexicon Pharmaceuticals, Inc. Specifically, the study will test whether two different dose levels of LX1606 (250 mg or 500 mg, each given three times daily) improve control of symptoms and are safe in patients with carcinoid syndrome.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting